贝伐单抗是静脉给予每两至三个星期。
Bevacizumab is given intravenously every two to three weeks.
没有那些蛋白的患者使用曲妥单抗无效。
目前关于西妥昔单抗治疗乳腺癌的研究较少。
But there are few studies on Cetuximab for treating Breast Cancer.
目的探讨抗白念珠菌保护性单抗1b5的保护机制。
Objective To investigate the protective mechanism of MAb 1b5 against candida albicans.
结论：利妥昔单抗联合CHOP方案治疗DLBCL，疗效好，不良反应小。
Conclusion: Combination treatment of rituximab and CHOP is effective and of little side effect.
结论：利妥昔单抗联合CHOP方案治疗DLBCL，疗效好，不良反应小。
Conclusion: Combination treatment of rituximab and CHOP is effective and of little side effect.
应用推荐